retatrutide clinical trial data Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 conducted in the USA When will Retatrutide be available

Pilot study of the prevalence of binge eating disorder in non-alcoholic fatty liver disease patients

Glucose tolerance was also improved with the three highest doses of tirzepatide, and plasma insulin levels during an oral glucose tolerance test were increased in subjects treated with 15 mg tirzepatide vs placebo

Other GLP-1 medications, including Wegovy, Saxenda, Victoza, Byetta, or Bydureon If youre using other products for weight loss, including dietary supplements Its important to share your entire medical history with your provider

In this virtual appointment, youll have a real conversation about your health history, any medications youre currently taking, and the specifics of your weight management goals

Eligibility for GLP-1 or GLP-1/GIP microdose therapy is determined by a licensed healthcare provider based on your medical evaluation